lncRNA NKILA: a killer regulator.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Long non‑coding RNA NKILA regulates the JAK2/STAT3 pathway to exacerbate TGF‑β1‑mediated renal fibrosis.Molecular medicine reports · 2026
   Article
2. LncRNA NKILA inhibits HBV replication by repressing NF-κB signalling activation.Virologica Sinica · 2024
   Article
3. An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer.Non-coding RNA · 2023
   Review
4. lncRNAs in T lymphocytes: RNA regulation at the heart of the immune response.American journal of physiology. Cell physiology · 2021
   Review
5. LncRNA NKILA was upregulated in diabetic cardiomyopathy with early prediction values.Experimental and therapeutic medicine · 2019
   Article

Corrections and comments

• Comment on
  NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as